The influence of sex on left ventricular remodeling in arterial hypertension

Marijana Tadic1, Cesare Cuspidi2, Guido Grassi3

  • 1Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin, Augustenburgerplatz 1, 13353, Berlin, Germany. marijana_tadic@hotmail.com.

Insights

Hypertension impacts heart failure risk differently in men and women. Sex hormones influence cardiac remodeling, leading to varied left ventricular changes and heart failure prevalence between sexes.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Hypertension Research

Background:

  • Arterial hypertension is a primary cardiovascular risk factor for heart failure (HF).
  • Sex hormones significantly influence hypertension prevalence and target organ damage, particularly in women.
  • Left ventricular (LV) remodeling occurs in both sexes due to hypertension but differs in prevalence and manifestation.

Purpose of the Study:

  • To review sex-related differences in LV remodeling in patients with arterial hypertension.
  • To explore the underlying mechanisms, particularly the role of sex hormones, in these sex-specific changes.
  • To provide an updated overview of current data on hypertension-induced LV alterations.

Main Methods:

  • Literature review of studies investigating sex differences in hypertension and heart failure.
  • Analysis of data on left ventricular structural, functional, and mechanical changes.
  • Examination of the role of sex hormones and biohumoral systems in cardiac remodeling.

Main Results:

  • Left ventricular hypertrophy prevalence is higher in men.
  • Data on LV diastolic dysfunction and mechanical changes show inconsistencies between sexes.
  • LV longitudinal strain is lower in hypertensive men, though this trend exists in healthy populations too.

Conclusions:

  • Sex hormones are key mechanisms driving sex-related LV remodeling in hypertension.
  • Significant sex-specific variations exist in LV remodeling and HF development.
  • Further research is needed to clarify sex-specific cutoffs for LV mechanical dysfunction.

Related Concept Videos

Nucleosome Remodeling02:54

Nucleosome Remodeling

Nucleosomes are the basic units of chromatin compaction. Each nucleosome consists of the DNA bound tightly around a histone core, which makes the DNA inaccessible to DNA binding proteins such as DNA polymerase and RNA polymerase. Hence, the fundamental problem is to ensure access to DNA when appropriate, despite the compact and protective chromatin structure.
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
10.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
584
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
450
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
601
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
108.5K